Aldeyra Therapeutics (NASDAQ:ALDX) is a biotechnology firm focused on the discovery, development, and commercialization of therapies for immune-mediated diseases. Their projects are primarily centered on addressing ocular and systemic conditions by controlling inflammatory and immune responses, aiming to meet unmet medical needs in these areas. Aldeyra's pipeline includes candidates for the treatment of dry eye disease, allergic conjunctivitis, and other serious health conditions. Their objectives revolve around leveraging their proprietary RASP (Reactive Aldehyde Species) technology platform to bring novel treatments to patients, aiming to improve quality of life through scientific innovation and effective therapeutic solutions. With a commitment to excellence in research and patient care, Aldeyra is dedicated to advancing its projects from clinical development to commercial success.